E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Non-insulin dependent diabetes mellitus |
Ikke-insulin krævende diabetes |
|
E.1.1.1 | Medical condition in easily understood language |
Type II diabetes |
Type II diabetes |
|
E.1.1.2 | Therapeutic area | Body processes [G] - Metabolic Phenomena [G03] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10012637 |
E.1.2 | Term | Diabetes with peripheral circulatory disorders |
E.1.2 | System Organ Class | 10047065 - Vascular disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10045248 |
E.1.2 | Term | Type II diabetes mellitus with other specified manifestations |
E.1.2 | System Organ Class | 10027433 - Metabolism and nutrition disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10045252 |
E.1.2 | Term | Type II diabetes mellitus without mention of complication |
E.1.2 | System Organ Class | 10027433 - Metabolism and nutrition disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10063624 |
E.1.2 | Term | Type II diabetes mellitus inadequate control |
E.1.2 | System Organ Class | 10027433 - Metabolism and nutrition disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10012640 |
E.1.2 | Term | Diabetes with unspecified complications |
E.1.2 | System Organ Class | 10027433 - Metabolism and nutrition disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10045242 |
E.1.2 | Term | Type II diabetes mellitus |
E.1.2 | System Organ Class | 10027433 - Metabolism and nutrition disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To validate the safety and efficacy of the RC decoction in a randomized, double blinded and placebo-controlled clinical trial in patients with Type 2 diabetes. |
At vurdere effekter og sikkerhed af RC afkog i et randomiseret, dobbelt-blind og placebo-kontrolleret kliniske forsøg med type 2-diabetes patienter. |
|
E.2.2 | Secondary objectives of the trial |
To clarify the mechanisms of action of the decoction
To evaluate any carry-over effects of the Rauvolfia-Citrus treatment over 18 months, i.e. up to 12 months after cessation of the intervention.
|
At finde ud af virkningsmekanismer af Rauvolfia-Citrus afkog
At finde ud af om der er ”carry-over” effekter af behandling med afkoget, optil 12 måneder efter ophør af behandling.
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Patients with type II diabetes who are 40 years old or more and are taking one or more anti-diabetic treatment |
Patienter med type II diabetes, som er 40 år eller mere og er under en eller flere anti-diabetiske behandlinger |
|
E.4 | Principal exclusion criteria |
The criteria for exclusion of responders to advertisement about the study are T2D patients with:
- clinically significant cardiovascular, renal, or liver disease (alanine aminotransferase >3 times the upper limit of normal);
- known allergies, heart problems and uncontrolled hypertension (BP > 180/100 mmHg after 5 min rest);
- pregnancy, breast-feeding women as well as those women with the possibility of getting pregnant (or not taking contraceptives);
- drug abuse or a psychiatric diagnosis or who prove to be difficult to work with during the first interviews. |
Kriterierne for udelukkelse fra forsøget er hvis patienter med type II diabetes har:
- Klinisk signifikant hjerte-, nyre- eller leversygdom (alaninaminotransferase> 3 gange højere end grænsen for normal);
- Kendte allergier, hjerteproblemer og ukontrolleret hypertension (BT>180/100 mmHg efter 5 min hvile);
- Gravide, ammende kvinder samt de kvinder med mulighed for at blive gravid (eller ikke tager kontraceptiva);
- Stofmisbrug eller en psykiatrisk diagnose, eller dem som viser sig at være vanskeligt at arbejde med i de første interviews. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Normalization of HbA1c or 6 months of treatment |
Normalisering af HbA1c eller 6 måneders behandling |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
The HbA1c value and other biochemical parameters will be measured at the clinic visits of the study participants to Frederiksberg hospital Clinical Biochemistry laboratory after 2, 4 and 6 months during the treatment phase. |
HbA1c-værdi og andre biokemiske parametre måles under klinikbesøg af forsøgsdeltagere til Klinisk Biokemisk laboratoriet på Frederiksberg Hospital, efter 2, 4 og 6 måneder i behandlingens fase. |
|
E.5.2 | Secondary end point(s) |
None. Participation will only be stopped before the 6 months treatment period is over if study participants experience adverse effects. |
Ingen. Forsøget stoppes for en enkelt deltager hvis vedkommende oplever uønsket bivirkninger. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Yes |
E.6.11 | Pharmacogenomic | Yes |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.4.1 | Number of sites anticipated in Member State concerned | 1 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Last visit of the last subject undergoing the trial |
Forsøget afsluttes efter sidste besøg af sidste deltagere. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |